We serve Chemical Name:3-Bromo-5,7-dimethylimidazo[1,2-a]pyrimidine CAS:6840-20-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![3-Bromo-5,7-dimethylimidazo[1,2-a]pyrimidine](https://a.dearchem.com/CAS2/6840-20-6.png)
Chemical Name:3-Bromo-5,7-dimethylimidazo[1,2-a]pyrimidine
CAS.NO:6840-20-6
Synonyms:3-bromo-5,7-dimethyl-imidazo[1,2-a]pyrimidine;Imidazo[1,2-a]pyrimidine,3-bromo-5,7-dimethyl
Molecular Formula:C8H8BrN3
Molecular Weight:226.07300
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.671g/cm3
Index of Refraction:1.687
PSA:30.19000
Exact Mass:224.99000
LogP:2.10860
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-bromo-5,7-dimethyl-imidazo[1,2-a]pyrimidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Imidazo[1,2-a]pyrimidine,3-bromo-5,7-dimethyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-bromo-5,7-dimethyl-imidazo[1,2-a]pyrimidine Use and application,Imidazo[1,2-a]pyrimidine,3-bromo-5,7-dimethyl technical grade,usp/ep/jp grade.
Related News: Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. 3-Bromo-5,7-dimethylimidazo[1,2-a]pyrimidine manufacturer Active pharmaceutical ingredients directly impact disease. 3-Bromo-5,7-dimethylimidazo[1,2-a]pyrimidine supplier The main API products include antihypertensive, psychotropic and anti-AIDS special APIs. Antihypertensive APIs are mainly pulic and sartan drugs, and they are the world’s major suppliers of pulic and sartan APIs. 3-Bromo-5,7-dimethylimidazo[1,2-a]pyrimidine vendor First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s. 3-Bromo-5,7-dimethylimidazo[1,2-a]pyrimidine factory Active pharmaceutical ingredients directly impact disease.
